Session 1 – Atrial Fibrillation

Chairmen: S. Themistoclakis (Mestre), A. Raviele (Mestre)

15:00-15:15  Atrial fibrillation and OSAS

  1. China (Mestre)

15:15-15:30 Modern Strategies and Device to detect atrial fibrillation: I watch?

  1. Zecchin (Trieste)

15:30-15:45  Antiarrhythmic therapy in AF

  1. Verlato (Cittadella, PD)

15:45-16:00 The role of ETE for NOAC patients undergoing CVE: pros and cons

  1. Cucchini (Bassano del Grappa, VI)

16:00-16:15 Current indications for AF ablation

  1. Rossillo (Vicenza)

16:15-16:30  Discussion

Session 2 – NOAC in selected population

Chairmen: V. Pengo (Padova), Giuseppe Patti (Novara)

16:30-16:45  Elderly patient

  1. Bonanome (Venezia)

16:45-17:00  DES and NOAC

  1. Pasquetto (Padova)

17:00-17:15  Renal disease

  1. Bonmassari (Trento)

17:15-17:30  Pulmonary embolism and long term therapy

  1. Squizzato (Varese)

17:30-17:45 Discussion

17:45-18:15 Coffee Break



Chairmen: A. Squizzato (Varese), F. Ribichini (Verona)

18:15-18:30  Compass Trial and Perypheral Arthery Disease

  1. Anselmi (Verona)

18:30-18:45  Entrust-AF PCI

  1. Patti (Novara)

18:45-19:00  Augustus trial, new therapeutic strategies in Coronary Artery Disease

  1. Ferri (Padova)

19:00-19:15  Anticoagulation in fragile patients: therapeutic options

  1. Pengo (Padova)

19:15-19:30 Discussion

19:30-20:00 Lectura magistralis

What is the future role of the aspirin for the cronic arteriopathy?

  1. Ribichini (Verona)

FRIDAY, MAY 8, 2020


Session 4 – Aortic Valve Interventions (part 1)

Chairmen: F. Bedogni (Milano), G. Gerosa (Padova)

9:00-9:15       NEW Insights From the PARTNER 3 Trial

  1. Caprioglio (Vicenza)

9:15-9:30       NEW Insights From the Evolut Low-Risk Trial

  1. Ribichini (Verona)

9:30-9:45       TAVR in lower risk patients: Interventional view

  1. Reimers (Milano)

9:45-10:00      TAVR in lower risk patients: Surgical view

  1. Mangino (Mestre)

10:00-10:15 Discussion

10:15-10:30  Coffee Break


Session 5 – Aortic Valve Interventions (part 2)

Chairmen: A. Ramondo (Brescia), F. Ribichini (Verona)

10:30-10:45  TAVR in moderate aortic stenosis with heart failure

  1. Fraccaro (Padova)

10:45-11:00  Strokes after TAVR are rare and cerebral protection is unnecessary

  1. Fiocca (Milano)

11:00-11:15  TAVR with high risk for coronary obstruction: management strategies

  1. Ramondo (Brescia)

11:15-11:30  TAVR for bicuspid aortic valve disease: clinical trial updates, anatomic considerations and optimizing procedural outcomes

  1. Cernetti (Treviso)

11:30-11:45 Discussion




Session 6 –  Mitral valve regurgitation (part 1)

Chairmen: G. Tarantini (Padova), F. De Marco (Milano)

11:45-12:00 A post-COAPT update: new data and next steps for mitral valve repair

  1. Favero (Treviso)

12:00-12:15  MITRA-FR vs. COAPT: lessons from two trials with diametrically opposed results.

  1. Saccà (Mirano, VE)

12:15-12:30  Patient selection the echocardiography view

  1. Agricola (Milano, VE)

12:30-12:45 New device: “Pascal”-Edwards life science

  1. Berti (Massa)

12:45-13:00 Discussion

13:00-13:30  Lectura magistralis

What future for the aortic stenosis correction?

  1. Tarantini (Padova)

13:30-15:00 Lunch and poster session




Session 7 – Mitral regurgitation (part 2)

Chairmen: F. Caprioglio (Vicenza), L. Favero (Treviso)

15:00-15:15  Percutaneus anuloplasty: technique and results

  1. De Marco (Milano)

15:15-15:30  New borders: tricuspid valve

  1. Pasquetto (Padova)

15:30-15:45  Neocorde an efficacy tecnology

  1. Gerosa (Padova)

15:45-16:00  Latest techniques and results in minimally invasive mitral surgery

  1. Salvador (Vicenza)

16:00-16:15 Discussion




Session 8 – Interatrial septum

Chairmen: F. Paladin (Venezia), G. Pesarini (Verona)

16:15-16:30  When should I close the PFO?

  1. Pedon (Cittadella, PD)

16:30-16:45  PFO occlusion: a large number of devices

  1. Rigatelli (Rovigo)

16:45-17:00 PFO and migraine

  1. Quatrale (Mestre)

17:00-17:15  DIA: when interventional cardiology and when surgery?

  1. Ronco (Mestre)

17:15-17:30 Discussion

17:30-17:45 Coffee Break


Session 9 – LAA

Chairmen: G. Minniti (Treviso), G. Pasquetto (Padova)

17:45-18:00  LAA occlusion criteria for intervention and expert consensus documents

  1. Pesarini (Verona)

18:00-18:15  LAA occlusion: device selection

  1. Di Pede (San Donà di Piave, VE)

18:15-18:30  Pre and post-procedure therapeutic option

  1. Turiano (Belluno)

18:45-19:00  Surgical option of the LAA occlusion

  1. Minniti (Treviso)

19:00-19:15 Discussion

19:15-19:45  Lectura magistralisGalileo and Copernico, between Faith and Science

  1. Thiene (Padova)





Session 10 – CAD and new anti-platelet strategies

Chairmen: C. Bilato (Arzignano, VI), R. Valle (Chioggia, VE)

9:00-9:15       Long DAPT therapy: who and why?

  1. Bilato (Arzignano, VI)

9:15-9:30       Roule of aspirin: is it still necessary?

  1. Valle (Chioggia, VE)

9:30-9:45       NSTEMI: pre-treating or not?

  1. Cacciavillani (Padova)

9:45-10:00     Roule of cangrelor in ACS and stable CAD

  1. Muraglia (Trento)

10:00-10:15 Discussion

10:15- 10:45 Lectura magistralis | From aspirin to new antiplatelet agents

  1. Patrono (Roma)

10:45-11:00  Discussion

11.00-11:15 Coffee Break


Session 11 – Peripherical Artery Disease

Chairmen: C. Patrono (Roma), F. Grego (Padova)

11:15-11:30  New option on carotid artery disease

  1. Cagliari (Mestre)

11:30-11:45  New drug eluting stent for femoral artery: are a new frontier?

  1. Dorrucci (Mestre)

11:45-12:00  Distal PAD treatment strategy

  1. Antonello (Padova)

12:00-12:15  Diabetic foot: which is the best team?

  1. Manzi (Abano Terme, PD)

12:15-12:30 Discussion and closing remarks   

nike sneakers e scarpe sportive online Nuovi Jordans Outlet Online Nike Air Max Outlet Online Nike Free Outlet Online